Font Size: a A A

Clinical Observation Of En Bloc Transurethral Resection Of Bladder Tumor Combined With Tumor Submucosal Injection Of Pirarubicin

Posted on:2020-08-16Degree:MasterType:Thesis
Country:ChinaCandidate:Q W GengFull Text:PDF
GTID:2504306728499354Subject:Surgery
Abstract/Summary:PDF Full Text Request
ObjectiveTo evaluate the efficacy of en bloc transurethral resection of bladder tumor combined with tumor submucosal injection of pirarubicin in the treatment of non muscle-invasive bladder cancer.MethodsThe clinical data of 80 cases with NMIBC treated with endoscopic surgery during January 2017 to June 2018 were analyzed retrospectively.Age 31-89 years old,average(68.1 ± 14.8)years old.we review all patients were randomly divided intotwo groups,one ofgroup is en bloc transurethral resection of bladder tumor combined with tumor submucosal injection of pirarubicin.another group is TURBt.and record two groups of general information,operation time,tumor size,hospitalization time,tumor recurrence rate.The data were processed by using SPSS 20.0,the results were expressed as mean ± standard deviation,and the independent sample t-test was used and compare the count data using a chi-square test.There is a statistically significant(P<0.05),there is no statistical difference(P > 0.05).Results80 cases were treated with surgery,statistical results,The operation time(min): experimental group:(52.08±18.08)min,control group:(42.18±11.52)min,the difference between the two groups was considered statistically significant(P<0.05);Postoperative bladder irrigation time(h): experimental group:(13.24 ± 1.71)h;control group:(29.12 ±3.43),statistically significant difference between the two groups(P <0.05);Indwelling time of catheter(d): experimental group:(4.20±0.91)d,control group(4.64±1.32)d,there was no statistical difference between the two groups(P>0.05);Hospitalization time(d)Experimental group:(7.18±2.08)d,control group:(8.05±1.94)d;There were statistically significant(P<0.05);The number of postoperative tumor recurrences during the follow-up period: experimental group: 2/40(5.00%),control group: 11/40(27.50%),statistically there were significant difference between the two groups(P<0.05).ConclusionIn treating NMIBC,en bloc transurethral resection of bladder tumor combined with tumor submucosal injection of pirarubicin,compared with TURBT: Postoperative bladder irrigation timeis short;The tumor recurrence rate can be reduced.
Keywords/Search Tags:bladder cancer, en bloc transurethral resection, pirarubicin, tumor submucosal injection, recurrence
PDF Full Text Request
Related items
Clinical Study Of Trans-urethral Laser En-bloc And Resection In The Treatment Of Non-muscle Invasive Bladder Cancer
Study On The Recurrence Rate Of Non Muscular-invasive Bladder Cancer With The Diameter Of Less Than Or Equal To 3cm In Different Surgical Methods
Efficiency Comparison Of Intravesical Instillation THP And HCPT After Transurethral Resection Of Bladder Tumor In Superficial Bladder And The Relationship Between Recurrence Rate And Clinical Characteristics
Comparison Of Endoscopic Therapies For Non-muscle Invasive Bladder Cancer:Transurethral En Bloc Resection Versus Traditional Transurethral Resection Of Bladder Tumor
Curative Effect Observation Of Transurethral Bladder Tumor Endoscopic Submucosal Dissection And Transurethral Resection For Superficial Bladder Cancer
Preventive Effect Of Pirarubicin On Recurrence Of Non-muscle Invasive Bladder Cancer After Resection
Benefit Analysis Of En Bloc Transurethral Resection With Laser In The Treatment Of Non-muscle-invasive Bladder Tumor
Clinical Study On The Treatment Of En Bloc Transurethral Resection Of Bladder Tumors With Needle Electrode And Repeat Transurethral Resection For Bladder Cancer
Efficacy Analysis Of Thulium Laser En-bloc Resection Of Bladder Tumor Versus Plasm Akinetic Transurethral Resection Of Bladder Tumor For Non-muscle Invasive Bladder Cancer
10 Clinical Research Of Intraoperative Submucosal Multiple Injection Of Interleukin-2(IL-2) And Intravesical Instillation Of Gemcitabine(GEM) In The Treatment Of Non-muscle-invasive Bladder Cancer(NMBIC) During Transurethral Resection Of Bladder Tumor(TUR-Bt